TD-HS856016

Ixekizumab(TD-HS856016) is a research-grade recombinant antibody targetingCTLA-8. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG4-kappa

Monoclonal

CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

Q16552

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

LY2439821, 1143503-69-8

Ixekizumab is a humanized monoclonal antibody to interleukin-17A which acts as an antiinflammatory agent and is used to treat moderate-to-severe plaque psoriasis. Ixekizumab has not been linked to serum enzyme elevations during therapy or to instances of idiosyncratic acute liver injury.• The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781• Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability., PMID:26431948• IL-17A functions and the therapeutic use of IL-17A and IL-17RA targeted antibodies for cancer treatment., PMID:37579542• The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases., PMID:34863654• IL-17 for therapy., PMID:28633806• Association Between., PMID:35271496• Vunakizumab: First Approval., PMID:39497021• The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies., PMID:31278139• IL-17A Modulates Peritoneal Macrophage Recruitment and M2 Polarization in Endometriosis., PMID:32117261• Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F., PMID:32973785

SEC-HPLC detection for Research Grade Ixekizumab.　　|　Detects Human IL17A in indirect ELISAs.　　|　Flow-cytometry using anti-human IL17A antibody. Jurkat cells were fixed and permeabilized, then stained with an irrelevant antibody (Blue Histogram) or an anti-human IL17A monoclonal antibody (Catalog HS856016, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.　　|　SDS-PAGE for Research Grade Ixekizumab.　　|　Western blot analysis was performed using anti-IL17A monoclonal antibody at 1μg/ml on various samples.Lane 1:recombinant human IL17A (Catalog No:TD-HS856011), 50ngLane 2:recombinant human IL17A (Catalog No:TD-HS856011), 30ngLane 3:recombinant human IL17A (Catalog No:TD-HS856011), 20ngLane 4:recombinant human IL17A (Catalog No:TD-HS856011), 10ng

For research use only. Not suitable for clinical or therapeutic use.